Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies

被引:72
作者
Lorenz, P
Baker, BF
Bennett, CF
Spector, DL
机构
[1] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
[2] ISIS Pharmaceut, Carlsbad, CA 92008 USA
关键词
D O I
10.1091/mbc.9.5.1007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Antisense oligonucleotides are powerful tools for the in vivo regulation of gene expression. We have characterized the intracellular distribution of fluorescently tagged phosphorothioate oligodeoxynucleotides (PS-ONs) at high resolution under conditions in which PS-ONs have the potential to display antisense activity. Under these conditions PS-ONs predominantly localized to the cell nucleus where they accumulated in 20-30 bright spherical foci designated phosphorothioate bodies (PS bodies), which were set against a diffuse nucleoplasmic population excluding nucleoli. PS bodies are nuclear structures that formed in cells after PS-ON delivery by transfection agents or microinjection but were observed irrespectively of antisense activity or sequence. Ultrastructurally, PS bodies corresponded to electron-dense structures of 150-300 nm diameter and resembled nuclear bodies that were found with lower frequency in cells lacking PS-ONs. The environment of a living cell was required for the de novo formation of PS bodies, which occurred within minutes after the introduction of PS-ONs. PS bodies were stable entities that underwent noticeable reorganization only during mitosis. Upon exit from mitosis, PS bodies were assembled de novo from diffuse PS-ON pools in the daughter nuclei. In situ fractionation demonstrated an association of PS-ONs with the nuclear matrix. Taken together, our data provide evidence for the formation of a nuclear body in cells after introduction of phosphorothioate oligodeoxynucleotides.
引用
收藏
页码:1007 / 1023
页数:17
相关论文
共 73 条
[1]   hnRNP A1 binds promiscuously to oligoribonucleotides: Utilization of random and homo-oligonucleotides to discriminate sequence from base-specific binding [J].
AbdulManan, N ;
Williams, KR .
NUCLEIC ACIDS RESEARCH, 1996, 24 (20) :4063-4070
[2]   Antisense oligonucleotides: Towards clinical trials [J].
Agrawal, S .
TRENDS IN BIOTECHNOLOGY, 1996, 14 (10) :376-387
[3]  
Agrawal Sudhir, 1995, Current Opinion in Biotechnology, V6, P12, DOI 10.1016/0958-1669(95)80003-4
[4]   The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-asscciated nuclear bodies at very early times in infected permissive cells [J].
Ahn, JH ;
Hayward, GS .
JOURNAL OF VIROLOGY, 1997, 71 (06) :4599-4613
[5]   IMMUNOCYTOCHEMICAL ANALYSIS OF THE COILED BODY IN THE CELL-CYCLE AND DURING CELL-PROLIFERATION [J].
ANDRADE, LEC ;
TAN, EM ;
CHAN, EKL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) :1947-1951
[6]   2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells [J].
Baker, BF ;
Lot, SS ;
Condon, TP ;
ChengFlournoy, S ;
Lesnik, EA ;
Sasmor, HM ;
Bennett, CF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :11994-12000
[7]   ADVANCES IN THE SYNTHESIS OF OLIGONUCLEOTIDES BY THE PHOSPHORAMIDITE APPROACH [J].
BEAUCAGE, SL ;
IYER, RP .
TETRAHEDRON, 1992, 48 (12) :2223-2311
[8]   BINDING, UPTAKE, AND INTRACELLULAR TRAFFICKING OF PHOSPHOROTHIOATE-MODIFIED OLIGODEOXYNUCLEOTIDES [J].
BELTINGER, C ;
SARAGOVI, HU ;
SMITH, RM ;
LESAUTEUR, L ;
SHAH, N ;
DEDIONISIO, L ;
CHRISTENSEN, L ;
RAIBLE, A ;
JARETT, L ;
GEWIRTZ, AM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1814-1823
[9]  
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
[10]  
BENNETT CF, 1994, J IMMUNOL, V152, P3530